Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (195)	3/16/2004 5:58:25 PM
From: Icebrg	Read Replies (1) of 946

Bad timing ? 09.03.2004 11:49 GPC Biotech stellt Entwicklung von Bryostatin ein München/Frankfurt (vwd) - Die GPC Biotech AG, Martinsried, hat die Entwicklung der beiden Medikamenten-Kandidaten Bryostatin-1 und Bryologs eingestellt. Für Bryostatin-1 sei bislang kein Verabreichungsschema gefunden worden, das eine Wirksamkeit des Präparats ohne akzeptable Nebenwirkungen ermöglicht hätte, teilte Vorstandsvorsitzender Bernd R. Seizinger am Dienstag in Frankfurt mit. Auch der Wirkstoff Bryologs habe keine ausreichende Wirksamkeit gegen Tumoraktivitäten gezeigt. On its pipeline, GPC Biotech said it has decided to discontinue development of Bryostatin-1, a therapeutic oncology compound. GPC in-licensed Bryostatin-1 from Arizona State University in 2001. This is a little bit strange as there are a fair number of NCI-sponsored trials ongoing for the drug. I suppose that CTIC would be happy to in-lincense this drug if it is available. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next